Tenax Therapeutics, Inc. (TENX) stock
TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.42−0.06 (-4.05%)
Close on Nov 17, 2026Market cap $53.14MP/E –Yield –
Earnings
Tenax Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.31
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Tenax Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 9, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | – | – | -$0.31 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 31, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 10, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025after the close | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025after the close | – | – | -$0.27 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024before the open | – | – | $0.19 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024after the close | – | – | -$1.83 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024before the open | – | – | -$3.12 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 28, 2024before the open | – | – | – | Release |
| Q4 FY2014ended Apr 30, 2014 | Jul 30, 2014during market hours | – | – | – | Filing |
| Q4 FY2013ended Apr 30, 2013 | Jun 27, 2013during market hours | – | – | – | Filing |
| Q3 FY2013ended Jan 31, 2013 | Mar 19, 2013during market hours | – | – | – | Filing |
| Q2 FY2013ended Oct 31, 2012 | Dec 17, 2012before the open | – | – | – | Filing |
| Q1 FY2013ended Jul 31, 2012 | Sep 20, 2012after the close | – | – | – | Filing |
| Q4 FY2012ended Apr 30, 2012 | Jul 25, 2012after the close | – | – | – | Filing |
| Q3 FY2012ended Jan 31, 2012 | Mar 16, 2012after the close | – | – | – | Filing |
| Q2 FY2012ended Oct 31, 2011 | Dec 19, 2011before the open | – | – | – | Filing |
| Q1 FY2012ended Jul 31, 2011 | Sep 20, 2011after the close | – | – | – | Filing |
| Q4 FY2011ended Apr 30, 2011 | Jul 15, 2011during market hours | – | – | – | Filing |
| Q1 FY2011ended Jul 31, 2010 | Sep 10, 2010after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Tenax Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Tenax Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Tenax Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- News
- News
- Results
- News
- Results
- News
- Results
- News
- Results
- News
- Results
- Results
See a number that looks wrong?